Practice Parameters for the Dopaminergic Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder

Littner, Michael R.; Kushida, Clete A.; Anderson, William M.; Bailey, Dennis; Berry, Richard B.; Hirshkowitz, Max; Kapen, Sheldon; Kramer, Milton; Lee‐Chiong, Teofilo; Li, Kasey K.; Loube, Daniel I.; Morgenthaler, Timothy I.; Wise, Merrill S.

doi:10.1093/sleep/27.3.557

Cited by 145 publications

(69 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Donepezil, pramipexole and L -dopa have also been reported to be effective, though experience is limited to case reports [65, 66]. Restless legs syndrome is readily responsive to DAs [67, 68]. Use of hypnotics should be limited to cases that do not respond to behavioral modifications and other measures, as there are no efficacy data for specific hypnotic agents in PD.…”

Section: Treatment Of Non-motor Symptomsmentioning

confidence: 99%

Treatment of Early Parkinson’s Disease

et al. 2009

View full text Add to dashboard Cite

The management of early Parkinson’s disease (PD) involves the treatment of motor symptoms, and, increasingly, non-motor symptoms. Given the fast pace of clinical research in PD, clinicians are faced with the challenge of integrating the latest findings into the ongoing care of individual PD patients. Part 1 of this 2-part article reviews efficacy and safety data for the newest PD treatment options, as well as for established therapies. Part 2 of the article, presented here, reviews key data relevant to the assessment of potential neuroprotective therapies and the treatment of non-motor symptoms.

show abstract

Section: Treatment Of Non-motor Symptomsmentioning

confidence: 99%

Treatment of Early Parkinson’s Disease

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Otro trastorno del sueño, el síndrome de piernas inquietas 34 , tampoco requiere una PSG para su diagnóstico, ya que este ha de ser puramente clínico. Únicamente se recomienda la PSG en caso de duda diagnóstica o de asociación a otro trastorno del sueño (muy común es la coexistencia de SPI con SAOS).…”

Section: Patología Del Sueñounclassified

Basic techniques of electroencephalography: principles and clinical applications

Ramos-Argüelles

Morales

Egozcue

et al. 2010

An Sist Sanit Navar

View full text Add to dashboard Cite

RESUMENEl electroencefalograma es una técnica de exploración funcional del sistema nervioso central (SNC), de relativa antigüedad, pero que aún hoy día sigue siendo una herramienta de gran ayuda para el clínico en el diagnóstico y seguimiento de algunas patologías, como pueden ser la epilepsia, las encefalopatías, alteraciones del estado de conciencia, infecciones del SNC, etc. Es, por otro lado, una herramienta diagnóstica con aplicaciones que están en plena expansión, en combinación con otras técnicas neurofisiológicas, como es en el campo del estudio y diagnóstico de la patología de sueño (polisomnografía, test de latencias múltiples del sueño...) y la monitorización intraoperatoria junto con los potenciales evocados somatosensoriales. Se describen en este trabajo cuáles son los fundamentos técnicos de la electroencefalografía, haciendo especial hincapié en sus principales aplicaciones clínicas y en las perspectivas del futuro.Palabras clave. Electroencefalografía. Utilidades clíni-cas. Técnicas básicas. Epilepsia. Patrones EEG. ABSTRACTThe electroencephalogram is a technique for the functional exploration of the central nervous system (CNS). It is a relatively old technique but even today it continues to be a tool of great assistance to the clinician in diagnosing and treating certain pathologies, such as epilepsy, encephalopathies, alterations to the state of consciousness, CNS infections, etc. On the other hand, it is a diagnostic tool whose applications are expanding in combination with other neurophysiological techniques, such as in the field of the study and diagnosis of sleep pathology (polysomnography, multiple sleep latency test...) and in intraoperative monitoring together with somasensory evoked potentials. This article describes the basic techniques of electroencephalography, with special emphasis on its main clinical applications and on future perspectives.

show abstract

“…On the basis of this increasing scientifi c literature, several evidence-based reviews have been recently carried out and practice recommendations proposed. [45][46][47][48][49][50][51] Differently from evidence-based reviews that mention specifi c drugs and specifi c dosages for RLS, practice recommendations recognize levodopa and dopamine agonists as the preferred fi rst-line treatments for RLS.…”

Section: Rotigotine For Rlsmentioning

confidence: 99%

Restless legs syndrome: differential diagnosis and management with rotigotine

Merlino

Serafini²,

Robiony³

et al. 2009

NDT

View full text Add to dashboard Cite

RLS is a common sleep disorder with distinctive clinical features. The prevalence of RLS in Caucasians and North Americans ranges from 5% to 10%. However, only some of these subjects (almost the 3% of the general population) report being affected by a frequent and severe form of the sleep disorder. RLS is diagnosed clinically by means of four internationally recognized criteria that summarize the main characteristics of the sleep disorder. Besides the essential criteria, supportive and associated features of RLS have been established by experts in order to help physicians treat patients with doubtful symptoms. Several clinical conditions may mimic this sleep disorder. In order to increase the sensibility and specifi city of RLS diagnosis, doctors should perform a meticulous patient history and then an accurate physical and neurological examination. Dopamine agonists are recognized as the preferred fi rst-line treatment for RLS. Rotigotine is a non-ergoline dopamine agonist with selectivity for D1, D2 and D3 receptors. The drug is administered via transdermal patches which release rotigotine for 24 hours. Four clinical trials demonstrated that this compound is able to improve RLS symptomatology with few and moderate adverse events. Head to head trials are required to compare the effi cacy and tolerability of rotigotine with other dopamine agonists administered via oral intake. Rotigotine has been approved by the FDA and EMEA for Parkinson's disease. For the treatment of moderate to severe idiopathic RLS, rotigotine has been recommended for approval by the EMEA and is under review by the FDA.

show abstract

Practice Parameters for the Dopaminergic Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder

Cited by 145 publications

References 1 publication

Treatment of Early Parkinson’s Disease

Treatment of Early Parkinson’s Disease

Basic techniques of electroencephalography: principles and clinical applications

Restless legs syndrome: differential diagnosis and management with rotigotine

Contact Info

Product

Resources

About